Kornimate/medical-research-clean huggingface dataset:
sma targeted magnetic stimulation against auditory verbal hallucinations

Conditions: Auditory Hallucination

Summary: auditory verbal hallucinations (avh) are prevalent among patients with psychiatric disorders. not only being highly stressful and functionally impairing, avh often persist despite treatment. recent attempts to treat avh with add-on repetitive transcranial magnetic stimulation (rtms) when targeting the temporoparietal junction (tpj), a language node in the brain, has gained limited success. the aim of this investigation is to reduce avh with rtms using continous theta-burst stimulation over a novel target, the supplementary motor area (sma), in participants with frequent avh, while also assessing potential neurophysiological mechanisms underlying the symptom.


Eligibility criteria:
inclusion criteria: inclusion criteria for the avh group: * reported avh with a minimum frequency of at least daily occurrence, with onset more than one month ago * stable psychopharmacological treatment past month inclusion criteria for the non-avh control group * reporting no occurrences of avh for the past year * stable psychopharmacological treatment past month inclusion criteria for the healthy control group * no life-time occurrence of avh * no history of psychiatric disorders as assessed with a mini-international neuropsychiatric interview (m.i.n.i.) exclusion criteria: * ferromagnetic or electromagnetic implants that may pose a risk during magnetic resonance imaging (mri) and/or ctbs * a history of epilepsy * pregnancy * current substance use disorder or a history of alcohol use disorder as assessed with alcohol use disorders identification test (audit), drug use disorders identification test (dudit), urine samples with test for illicit drugs and phosphatidylethanol (peth) * daily benzodiazepine use * factors that make the participant unlikely to be able to complete the study
nutritional support for hiv-tuberculosis co-infected adults in senegal, west africa

Conditions: HIV and Tuberculosis Co-infection

Summary: food insecurity can contribute to poor adherence to both tuberculosis treatment and antiretroviral therapy (art). interventions that target food insecurity have the potential to improve treatment adherence and decrease mortality. the goals of this study were to determine the cost, feasibility, acceptability, and potential impact of implementing nutritional support to improve adherence and treatment completion among hiv-tb co-infected adults in the casamance region of senegal, west africa.


Eligibility criteria:
inclusion criteria: * hiv-tuberculosis co-infection * age ≥18 years * initiating treatment for tuberculosis * provide written informed consent exclusion criteria: • unwilling or unable to provide written informed consent
influence of electronic patient reported outcomes (eproms) in surgical therapy for prostate cancer on postoperative outcome

Conditions: Prostate Cancer

Summary: the study investigates the influence of structured follow-up using eproms in the 1st year after prostatectomy on the postoperative course. it will be examined whether this intervention leads to early detection of postoperative symptoms and whether the subsequent initiation of further measures lead to an improvement of incontinence, symptom burden, quality of life and patient competence.

pro-p is planned as a multicenter, prospective, and two-arm randomized control group study in which eproms will be performed in a standardized fashion once before and six times (intervention group) or three times (control group) after primary prostatectomy in patients with pca. proms are collected either web-based or through a dedicated app and entered by the patient using either a mobile device or computer. patients are invited to enter eproms into the app or web tool through email and app-driven push messages. patients who are incontinent (at least one pad in 24 hours) at the 6-week postoperative survey are randomized into two groups: the intervention group and the control group. in the intervention group, when the respective questionnaire cut-off values are exceeded in the eprom survey, an alarm is triggered at the treating prostate cancer center and contact is made by the center as well as subsequent measures, if necessary. this is done at 6 weeks postoperatively and at 12, 18, 24, 36 and 52 weeks postoperatively. in the control group, eproms are recorded 24 and 52 weeks after radical prostatectomy, but without triggering an alarm with subsequent measures - the control group thus receives treatment in accordance with the current clinical routine. the mechanisms of action of the intervention will be investigated within the framework of a qualitative process evaluation. characteristics on the patient level (e.g., treatment-related attitudes, comorbidity, social support), on the practitioner level (e.g., communication skills), on the organizational level, and the interactions between the levels (e.g., patient-doctor relationship) will be explored. the goal is to develop an intervention model, or to describe the effective elements of the intervention.

Eligibility criteria:
inclusion criteria: * age ≥ 18 y * legal capacity * sufficient knowledge of the german language * prostate carcinoma, tnm t1-4 nx n0-1 m0-1c * primary radical prostatectomy planned * mobile input device or pc available * ability to either receive emails or install a special app on cell phone and receive push messages, with guidance or assistance if necessary * ability to complete electronic questionnaires, with guidance or assistance if necessary exclusion criteria: * palliative treatment situation (life expectancy \< 1 year) * preoperative urinary incontinence (at least one pad per 24 hours)
a phase 1 study of arq 197 in patients with solid tumors

Conditions: Cancer

Summary: this is a phase 1, open label, dose escalation study of arq 197 in patients with advanced/recurrent solid tumors. the purpose of this study is to determine the safety, tolerability and recommended phase 2 dose (rp2d) of arq 197.


Eligibility criteria:
inclusion criteria: * patients who did not respond or are refractory to available therapy or for whom no standard effective systemic therapy exists. * karnofsky performance status (kps) ≥ 70%, or eastern cooperative oncology group (ecog) performance status 0 to 1 * patients with adequate organ function exclusion criteria: * anti-cancer chemotherapy, hormonal therapy, radiotherapy, immunotherapy, or investigational agents within 4 weeks prior to the first dose of arq 197 * known symptomatic brain metastases * pregnant or breastfeeding * uncontrolled intercurrent illness
hlh patients - a retrospective study

Conditions: Hemophagocytic Lymphohistiocytoses

Summary: monocentric, observational, retrospective, no profit study aimed to analyze factors that are significantly impacting the outcome of patients diagnosed with hlh.

retrospective data collection to study: type of hlh familial vs secondary, sex, age, presence of infectious cause, involvement central nervous system ( snc), hepatic involvement, presence of hemophagocytosis, presence of splenomegaly, presence of involvement of other organs, the value of neutrophils (pmn), the value of hemoglobin, platelets, albumin, triglycerides, ferritin, ldh, type of therapy and the response to therapy after 2 months

Eligibility criteria:
inclusion criteria: * have received hlh diagnosis according to hlh 2004 criteria * age ⥶18 years. * followed at our facility between january 2004 and december 2021 * whose parents have consented to participation and data processing exclusion criteria: * the study does not foresee specific exclusion criteria other than the non-compliance with the inclusion criteria
tecpr2 observational study

Conditions: TECPR2

Summary: the purpose of this study is to learn more about the disease progression in patients with a tecpr2 mutation.

a mutation in the tectonin beta-propeller repeat containing 2 (tecpr2) gene can disrupt the cellular process of autophagy resulting in neuronal cell death. this disruption leads to a form of spastic paraplegia with the additional disruption to involuntary body processes, such as respiration and thermoregulation. this study will provide valuable information about the natural progression of children with a tecpr2 mutation.

Eligibility criteria:
inclusion criteria: * written informed consent (and assent where appropriate) before any study procedures take place; * male or female; * 18 months to 12 years old, at enrollment; and * have a diagnosis of tecpr2-related disorder, as defined by biochemical criteria and/or genetic mutation analysis, and demonstrate clinical findings such as autophagy, developmental delay, hypotonia, or other positive findings. exclusion criteria: * subject is unable to comply with study requirements; or * have any other concurrent condition that, in the opinion of the investigator, would make the subject unsuitable for the study.
neurosurgery patient outcomes in treating spinal disorders

Conditions: Symptomatic Lumbar Disc Herniation; Symptomatic Grade I Lumbar Spondylolisthesis

Summary: the creation of a multi-center cooperative research group encompassing academic and community-based spinal practices . . .


Eligibility criteria:
inclusion criteria: * grade i degenerative or isthmic spondylolisthesis recalcitrant to non-invasive therapies for at least 3 months or lumbar degenerative disc herniation with radiculopathy refractory to non-invasive therapies for at least 6 weeks exclusion criteria: * history of previous lumbar spine surgery * significant motor weakness (3/5) (i.e. foot drop) * cancer, infection, or fracture * pregnancy
long-term impact of pneumococcal conjugate vaccine on carriage

Conditions: Pneumococcal Infections

Summary: pneumococcus is a major cause of morbidity and mortality. in 2000, a pneumococcal conjugate vaccine (pcv) was licensed for use in children and is now part of the routine childhood vaccine schedule. pcv is known to reduce invasive disease and protect against nasopharyngeal (np) acquisition of vaccine serotype pneumococci; it also results in an increased risk of nonvaccine serotype carriage. this study proposes to assess the longterm impact of vaccine on np carriage in a setting where there is intense antibody pressure on the ecology of the pneumococcus. a cross sectional study of pneumococcal np colonization among american indian children will be combined with surveillance for invasive disease in the same population. the purpose is to determine the impact of community wide pcv use on np colonization and the relationship with invasive disease. this longterm safety issue needs to be assessed to fully evaluate the impact of vaccine on np ecology and invasive disease.

there are four specific aims for this study: (1) to determine the overall and serotype specific prevalence and incidence of pneumococcal carriage among children and adults at high risk for carriage and disease in the era of routine pneumococcal conjugate vaccine (pcv) use compared with those measures in the same population prior to use of pcv vaccine; (2) to characterize the intrafamilial np transmission of clones among those living with children less than 8 years of age; (3) to determine the immune correlates of protection from serotype specific pneumococcal carriage among individuals immunized and not immunized with pcv; and (4) to determine the relative invasiveness of serotypes of pneumococcus during an era of widespread pcv use and compare this to the relative invasiveness of serotypes prior to routine use of pcv.

Eligibility criteria:
inclusion criteria for the family to participate. 1. at least one parent is a member of the navajo or white mountain apache tribe 2. family home is on or near the navajo or apache reservation 3. at least one child in the household is 8 years of age or younger (minimum age of eligibility: birth) 4. at least one child in the household is fully immunized with prevnar. 5. at least two people in the household will participate in the study 6. willingness to participate for a 6-month time period exclusion criteria for the family to participate. 1. family will be moving off reservation during the study period inclusion criteria for individuals. 1. living in the household 2. willing to participate for a 6-month time period exclusion criteria for individuals. 1. congenital anomalies of the nasopharynx -
rct to evaluate the cosmetic efficacy of demo-cosmetic active ingredient cls02021

Conditions: Overall Skin Appearance; Dry Skin; Eczema

Summary: this study will explore the potential of probiotic based, novel cosmetic active ingredient to rebuild the collagen based skin barrier with the overall aim to rejuvenate ageing or damaged skin, improve skin integrity, appearance, beauty, and support personal well-being and vitality.


Eligibility criteria:
inclusion criteria: 1. male and/or female subjects aged 18 to 69 years 2. subjects who have given and signed written informed consent 3. subjects who are willing to comply with the study requirements exclusion criteria: 1. subjects with any systemic disorder or face dermatoses including acne that would in any way confound interpretation of the study results (e.g. atopic dermatitis, eczema, or psoriasis) 2. subjects with a condition or receiving a medication and/or with a history of medical/surgical events which, in the opinion of the investigator, could compromise the safety of the subject or affect the outcome of the study 3. subjects with a history of skin cancer 4. subjects who have started, stopped or changed of hormonal treatment (contraception, thyroid ...) in the 3 months prior the study inclusion 5. subjects who are sensitive to any compound in the base cream 6. subjects who are sensitive to any active cosmetic compound including sphingomielinaze, hylauronic acid, lactic acid or lipothecoic acid 7. subjects who have used systemic drugs for more than 3 consecutive days related to antibiotics, anti-inflammatory, corticoids, anti-acneic in the 4 weeks prior to study inclusion 8. subjects who have used topical drugs for more than 3 consecutive days related to antibiotics, anti-inflammatory, corticoids, anti-acneic in the 4 weeks prior to study inclusion 9. subjects who have used scrub, anti-seborrheic topical cosmetic products and/or who have applied self-tanning products on face in the 1 week prior the study inclusion 10. subjects having applied any topical products on face (including make- up) the day of the study inclusion 11. subjects who have planned a major surgery during the study requiring hospitalization under general anesthesia and the use of systemic or topical drugs (e.g. antibiotics, anti-inflammatory) for more than 1 week 12. subjects belonging to the staff of the study center 13. subjects in an exclusion period or participating in another biomedical research study

Keywords: skin hydration cosmetic appearance skin health skin sensitiviry
influence of smoking on periodontal healing one year after active treatment

Conditions: Periodontal Diseases; Smoking

Summary: the aim of this study was to investigate whether cigarette smoking had any impact on the clinical outcomes 1 year after active periodontal treatment. eligible for the study were 5680 individuals 20-85 years, referred to the specialised clinic for periodontal treatment at gävle county hospital between the years of 1980 and 2015. before examination, all individuals filled in a questionnaire regarding their medical health, medication and smoking habits. excluded were edentulous individuals and where clinical data 1-year after active treatment, or smoking habits were missing (n=1453). complete data for analyses was available for 4227 individuals.


Eligibility criteria:
inclusion criteria: * individuals referred to a specialist clinic for periodontal treatment exclusion criteria: * edentulous individuals

Keywords: smoking periodontal treatment periodontal disease healing
serum copeptin in cirrhotic patients with spontaneous bacterial peritonitis

Conditions: Spontaneous Bacterial Peritonitis

Summary: current reports have demonstrated that copeptin predicts disease progression and prognosis in cirrhotic patients, independent of liver-specific scoring systems. to the best of our knowledge, few studies have addressed the association between copeptin and sepsis in cirrhotic patients, however, they were performed on different types of infections. therefore, we will conduct this study with a focus on it is possible role in patients with sbp.


Eligibility criteria:
inclusion criteria: * the diagnosis of liver cirrhosis will be based on clinical data and findings on abdominal ultrasound. the diagnosis of sbp will be based on the presence of at least 250 cells/ml pmnls in the ascitic fluid, with or without positive ascitic fluid culture in the absence of hemorrhagic ascites and secondary peritonitis exclusion criteria: * patients with heart failure, coronary insufficiency, advanced chronic respiratory disease, polyuria-polydipsia syndrome and hypotension or shock. * patients with chronic kidney disease treated with hemodialysis before admission. * patients with previous liver or kidney transplantation. * patients with intraabdominal malignancy. * patients with severe infection other than sbp. * patients who had received antibiotics before hospital admission.
brief intervention for families of teens treated in the emergency department for an alcohol-related event

Conditions: Alcohol Abuse

Summary: the purpose of this study is to compare the effectiveness of a brief family intervention in reducing alcohol use and alcohol-related problems among families of underage drinkers (13-17 years old) who are treated in a hospital emergency department for an alcohol-related event.

the long-term objectives of this research program are to develop effective interventions in health care settings for reducing problem drinking and associated problems among adolescents and to further enhance intervention approaches by identifying effective elements of treatment. the major purpose of this study is to compare a brief integrated individual and family intervention designed to reduce alcohol use and related problems to an enhanced standard care condition (standard care plus family assessment). the targeted population is underage drinkers (13-17 years old) who have been treated in an emergency department following an alcohol-related event. it is important to intervene with this population because alcohol-involved adolescents may be at higher risk for having continuing alcohol problems (fillmore, 1988; zucker, in press). the intervention is conceptualized as using a "teachable moment" (i.e., shortly after a salient event) to increase family interest in reducing harmful drinking. the experimental intervention integrates an individual motivational interview (mi) for the adolescent, based on our research group's prior work with this intervention, with a brief family intervention, the family check-up (dishion \& kavanagh, 2003). the experimental condition will be compared to standard care plus family assessment. this design allows us to test the added benefit of the brief family intervention compared to the benefits often derived from assessment without added treatment. follow-up interviews will be conducted at 3, 6, and 12 months after the baseline intervention to assess outcome. the specific aims of this proposal are to test the effectiveness of the experimental intervention in reducing alcohol-related problems, alcohol consumption, and other behavior problems compared to the enhanced standard care condition. second, we will examine whether depressed mood and behavior problems at baseline moderate the effects of the treatment conditions. we will also test whether individual factors (motivation to change behavior) and environmental factors (parent/family influence and peer influence) mediate the relation between the treatment condition and outcomes.

Eligibility criteria:
inclusion criteria: * child aged 13-17 years * receiving treatment at the approved medical emergency department * child living in a home with at least one parent or legal guardian exclusion criteria: * children who are suicidal, in police custody, not alert/oriented, non-english speaking, in severe pain, or who have sustained severe trauma * children with a history of prior substance abuse treatment

Keywords: alcohol substance abuse adolescent family functioning
ultrasound guided bilateral superficial cervical plexus block in patients undergoing total thyroidectomy.

Conditions: Analgesia Obtained With a Local Wound Infiltration of Lidocain; Analgesia Obtained With a Ultrasound Guided Cervical Plexus Block Using Lidocain; Postoperative Pain

Summary: the present study compared the efficacy of bilateral superficial cervical plexus block (bscpb) versus local wound infiltration (lwi) regarding the postoperative opioid consumption in patients undergoing total thyroidectomy

we performed a double-blind, randomised, controlled trial that recruited patients undergoing total thyroidectomy at the suez canal university hospital during the period between february 2019 and january 2021. patients were eligible if they were older than 20 years, had an american association of anesthesiologists' (asa) level of i-ii, and were scheduled for total thyroidectomy. we excluded patients with documented allergies to the study's intervention materials, moderate-to-severe obesity, \> 1st-degree heart block, chronic pulmonary or cardiac diseases, hepatic or renal dysfunction, and/or coagulopathies. all patients were required to fill out informed consent before enrollment. eligible patients were randomly allocated in a 1:1 ratio to receive bscpb or lwi using the computer software program (www. randmizer.org) and allocation sequences were done using opaque, closed envelopes. the bscpb group received bscbp (after general anaesthesia but before the start of surgery) from two syringes containing ropivacaine 0.5 % and lwi with saline. the lwi group received lwi with ropivacaine 0.5% and the bscpb from two syringes containing saline. the primary outcome of the present study was postoperative opioid consumption in the first postoperative day. the secondary outcomes included the total intraoperative fentanyl and isoflurane consumption, time to first required analgesic, and vas during the first 24 hours postoperatively.

Eligibility criteria:
inclusion criteria: asa i-ii, and were scheduled for total thyroidectomy - exclusion criteria: documented allergy to study's intervention, moderate-to-severe obesity, \> 1st-degree heart block, chronic pulmonary or cardiac diseases, hepatic or renal dysfunction, and/or coagulopathies. all patients were required to fill the informed consent before enrollment.
an multi-site prospective study to assess the efficacy and safety of mmf in the treatment of proliferative iga nephropathy(igan)

Conditions: IgA Nephropathy (IgAN)

Summary: in order to treat proliferative iga nephropathy(igan), the investigators designed an open, prospective, randomized parallel study to access the efficacy and safety of mmf compared to corticosteroid . patients who fulfill the inclusion criteria will be randomized in a 1:1 ratio to either the mmf group or corticosteroid group.

to access the efficacy and safety of mmf compared to corticosteroid in in treatment of proliferative iga nephropathy(igan).

Eligibility criteria:
inclusion criteria: 1. patients who signed written informed consent form 2. age between 18-60 years, female or male 3. diagnosed iga nephropathy (igan) by renal biopsy during 1 months 4. renal biopsy had: 10%\< crescents\<50%; endocapillary hypercellularity; or necrosis ,and interstitial fibrosis\<50%, 5. proteinuria\>1g/24h for two times exclusion criteria: 1. secondary iga nephropathy (igan); 2. egfr\<30ml/min/1.73m2.( mdrd formula) 3. liver disfunction; 4. uncontrolled hypertension 5. wbc \<3000/mm3 6. severe viral infection(hbv, hcv, cmv) within 3 months ofor known hiv infection. 7. diabetes or obesity(bmi\>28) ; 8. severe infection or central nervous system symptoms.

Keywords: mmf treatment iga nephropathy (igan)